VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IMDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IMDXInsight Molecular Diagnostics Inc.
$5.42$145M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIMDXBalance Sheet

Insight Molecular Diagnostics Inc. (IMDX) Balance Sheet

13Y historyFree accessUpdated daily

The company's financial position has deteriorated significantly, with equity shifting from $20.5 million in 2023Q4 to a negative $10.7 million by 2026Q1.

IMDX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Total Current Assets30.52M15.31M11.76M10.7M25.54M39.14M9.23M22.96M8.64M8.53M12.7M10.93M3.65M4.85M
Cash & Short-Term Investments28.2M11.58M8.64M9.43M20.43M33.85M7.82M22.45M8.46M8.36M12.41M10.54M3.54M4.73M
Cash Only28.2M11.58M8.64M9.43M19.99M32.95M7.14M22.07M8.03M7.6M10.17M8M257K101K
Short-Term Investments0000433K904K675K379K428K760K2.24M2.54M3.28M4.63M
Accounts Receivable157K1.13M1.61M484K2.01M1.44M203K0000000
Days Sales Outstanding96.21101.53313117.54766.58238.6360.93-------
Inventory382K446K410K00304K00000000
Days Inventory Outstanding115.8142.12131.16--142.62--------
Other Current Assets1.78M2.15M1.1M782K2.12M2.94M941K425K180K168K285K366K00
Total Non-Current Assets9.91M10.45M23.32M64.19M74.56M120.42M46.19M16.9M876K1.69M1.75M1.81M2.71M3.44M
Property, Plant & Equipment2.46M2.81M2.76M5.44M10.85M8.37M6.52M3.73M614K822K688K576K118K148K
Fixed Asset Turnover0.77x1.44x0.68x0.28x0.09x0.26x0.19x-------
Goodwill0000018.68M9.19M0000000
Intangible Assets0014.61M56.59M61.63M61.72M15.01M00746K988K1.23M1.47M1.71M
Long-Term Investments2.31M607K1.7M00013.42M10.96M00000-1.57M
Other Non-Current Assets7.45M7.03M4.26M2.16M2.07M31.65M1.94M2.21M262K120K75K001.57M
Total Assets40.43M25.76M35.08M74.89M100.09M159.56M55.42M39.86M9.52M10.22M14.45M12.73M6.36M8.29M
Asset Turnover0.05x0.16x0.05x0.02x0.01x0.01x0.02x-------
Asset Growth %-129.42%-26.58%-53.16%-25.18%-37.27%187.92%39.04%318.77%-6.83%-29.29%13.48%100.3%-23.3%-
Total Current Liabilities12.01M12.07M7.28M7.19M12.11M14.12M9M4.44M5.56M4.45M4.28M2.31M7.43M4.67M
Accounts Payable1.61M2.54M2.28M953K1.25M1.81M432K469K166K175K422K285K144K103K
Days Payables Outstanding377.44240.25729.04319.12468.59849.1685497.63108.39110.13398.01367.58--
Short-Term Debt1.76M1.81M0001.31M2.39M1.35M1.19M1.14M202K05.89M2.96M
Deferred Revenue (Current)00000000000000
Other Current Liabilities8.63M7.72M2.17M4.01M4.43M6.71M01.09M3.02M2.4M46K847K1.25M1.57M
Current Ratio2.54x1.27x1.62x1.49x2.11x2.77x1.03x5.17x1.55x1.91x2.97x4.72x0.49x1.04x
Quick Ratio2.51x1.23x1.56x1.49x2.11x2.75x1.03x5.17x1.55x1.91x2.97x4.72x0.49x1.04x
Cash Conversion Cycle-165.42-96.6-284.89---467.91--------
Total Non-Current Liabilities39.11M45.15M40.08M47.23M48.39M80.23M12.94M4.58M534K1.36M310K000
Long-Term Debt1.31M000001.51M1.91M347K1.07M0000
Capital Lease Obligations3.52M1.69M2.37M2.2M2.73M3.54M4.31M2.68M187K289K310K000
Deferred Tax Liabilities00000000000000
Other Non-Current Liabilities37.81M43.45M37.71M45.03M45.66M76.68M7.12M0000000
Total Liabilities51.12M57.22M47.35M54.42M60.5M94.35M21.94M9.02M6.09M5.81M4.58M2.31M7.43M4.67M
Total Debt3.07M3.5M3.66M2.87M3.54M5.68M8.63M6.17M1.72M2.5M512K05.89M2.96M
Net Debt-25.13M-8.09M-4.97M-6.56M-16.45M-27.27M1.49M-15.91M-6.32M-5.1M-9.66M-8M5.63M2.86M
Debt / Equity-0.29x--0.14x0.09x0.09x0.26x0.20x0.50x0.57x0.05x--0.82x
Debt / EBITDA-0.08x-------------
Net Debt / EBITDA0.65x-------------
Interest Coverage-522.35x-280.53x-721.18x-476.98x-223.24x-251.97x-122.75x-74.38x-71.94x-86.86x-397.86x-458.74x-2492.00x-
Total Equity-10.69M-31.46M-12.27M20.47M39.59M65.22M33.48M30.84M3.42M4.4M9.86M10.42M-1.07M3.62M
Equity Growth %-650.84%-156.35%-159.97%-48.31%-39.29%94.78%8.58%800.91%-22.26%-55.35%-5.33%1069.93%-129.71%-
Book Value per Share-0.31-1.03-0.942.687.1514.6710.2312.021.812.927.439.92-0.9911.14
Total Shareholders' Equity-10.69M-31.46M-12.27M20.47M39.59M65.22M33.48M30.84M3.42M4.4M9.86M10.42M-1.07M3.62M
Common Stock394.29M369.21M338.24M310.3M294.93M252.95M157.16M124.58M74.74M59.97M45.82M34.9M15.15M15.4M
Retained Earnings-405.05M-400.76M-350.54M-289.88M-260.68M-187.77M-123.68M-93.75M-71.32M-54.68M-35.3M-24.13M-15.4M-10.41M
Treasury Stock00000000000000
Accumulated OCI71K86K21K49K39K37K000-888K-654K-350K-822K-1.37M
Minority Interest00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity shortfall

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Equity and Capital Base

As reported in financial statements, IMDX's equity position has deteriorated significantly, shifting from a positive $20.5 million in 2023Q4 to a negative $10.7 million by 2026Q1, signaling a persistent erosion of shareholder value driven by continuous operating losses and the absence of a self-sustaining business model.

The consistent decline in equity suggests that the company is consuming its capital base to fund ongoing operations rather than building intrinsic value. This trajectory warrants close monitoring, as the transition into negative equity territory often limits future financing flexibility and increases the cost of capital.

Precarious Cash Runway and Liquidity

Based on reported figures, IMDX's cash reserves have fluctuated wildly, dropping from a peak of $31.0 million in 2025Q1 to $28.2 million in 2026Q1, which, when viewed against the company's high burn rate, suggests a limited buffer against potential operational shocks or further commercial delays.

While the current ratio of 2.54 appears superficially healthy, the underlying cash position remains highly sensitive to the timing of capital raises. Investors should interpret this liquidity profile as fragile, given that the company lacks the internal cash generation necessary to cover its substantial operating expenses.

Asset Quality and Goodwill Impairment

According to recent SEC filings, the total asset base has been heavily influenced by the complete write-down of $56.6 million in goodwill previously held on the balance sheet, which indicates that prior acquisition-related expectations have failed to materialize into tangible economic benefits for the firm.

The removal of goodwill from the balance sheet suggests a necessary, albeit painful, recognition that the company's past inorganic growth strategies did not create the anticipated value. The remaining asset mix is now primarily composed of cash and minimal PPE, reflecting a business that is essentially in a survival-oriented state.

Hidden Risks in Capital Structure

Financial data reveals that the company's reliance on debt, while relatively small at $3.1 million, creates an additional layer of risk given the negative equity position, which may indicate that the firm is operating under restrictive covenants that could be triggered by further financial deterioration.

The presence of debt on a balance sheet with negative equity is a significant red flag that suggests the company may be nearing a point where it must prioritize debt service over growth initiatives. This structure implies that any further operational setbacks could lead to a forced restructuring or highly dilutive equity issuance.

IMDX — Frequently Asked Questions

Quick answers to the most common questions about buying IMDX stock.

What are the total assets of Insight Molecular Diagnostics Inc. (IMDX)?

As of 2025, Insight Molecular Diagnostics Inc. (IMDX) had total assets of $25.8M including $15.3M in current assets.

How much debt does Insight Molecular Diagnostics Inc. (IMDX) have?

Insight Molecular Diagnostics Inc. (IMDX) carries total debt of $3.5M, offset by $11.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Insight Molecular Diagnostics Inc.?

Insight Molecular Diagnostics Inc. (IMDX) has total shareholders' equity (book value) of $-31.5M ($-1.03 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Insight Molecular Diagnostics Inc.'s current ratio and liquidity?

Insight Molecular Diagnostics Inc. (IMDX) reported a current ratio of 1.27x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.